EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Heidi Goerler
Axel Haverich
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goerler, H.
Right arrow Articles by Haverich, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goerler, H.
Right arrow Articles by Haverich, A.
Related Collections
Right arrow Coronary disease

Eur J Cardiothorac Surg 2007;32:560-566. doi:10.1016/j.ejcts.2007.01.071
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Safety of the use of Tissucol® Duo S in cardiovascular surgery: retrospective analysis of 2149 patients after coronary artery bypass grafting

Heidi Goerlera,*, Petra Oppelta, Ulrich Abelb, Axel Havericha

a Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl-Neuberg-Street 1, 30625 Hannover, Germany
b Center of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Received 25 October 2006; received in revised form 21 January 2007; accepted 29 January 2007.

* Corresponding author. Tel.: +49 511 532 2153; fax: +49 511 532 5404. (Email: goerler.adelheid{at}mh-hannover.de).

Objective: Fibrin sealant is widely used in almost all fields of surgery and has proved to be an effective therapeutic tool in cardiothoracic surgery. Nevertheless, there have been concerns about early bypass graft occlusion associated with the use of fibrin glue. This analysis has been performed to assess the risks and benefits of Tissucol® Duo S in coronary artery bypass grafting (CABG) surgery. Methods: Two thousand one hundred forty-nine patients were included in this retrospective study, 879 (40.9%) were intra-operatively treated with Tissucol® Duo S fibrin glue, 1270 (59.1%) did not receive fibrin glue (control group). Patient characteristics were documented according to the EuroScore. Intra- and postoperative data were collected. Primary endpoint of this study was the 30-day all-cause mortality rate in the Tissucol® Duo S treated group compared to the control group. Results: Mean age was 66.6 ± 9.4 years, 76.3% of the patients were male. There was an increased 30-day-mortality rate in the Tissucol® Duo S group compared to the control group (8.5 vs 3.5%, p < 0.001). In order to determine if and to what extent the apparent fibrin effect might be due to confounding effects from covariates, an adjustment for potential confounding was done. However, multivariable adjustment did not reduce the risk of fibrin glue below an odds ratio of 2.2. Conclusion: Although the apparent increase in mortality risk associated with the use of fibrin glue could not be eliminated statistically, we consider Tissucol® Duo S fibrin glue a safe and effective therapeutic tool in CABG surgery when it is applied correctly. Due to the retrospective character of this study some detailed information about the indication for the use of fibrin glue and its application is missing which may be important cofactors for mortality. For further clarification a prospective randomized study may be useful.

Key Words: Fibrin glue • Coronary artery bypass grafting • Myocardial infarction




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
P. Akhyari, H. Kamiya, A. Haverich, M. Karck, and A. Lichtenberg
Myocardial tissue engineering: the extracellular matrix.
Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 229 - 241.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
R. F. Nistor
Fibrin sealant in coronary artery bypass grafting surgery; reflection on risk and benefit
Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 317 - 317.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
P. Lamm and B. Reichart
Reply to Nistor
Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 318 - 318.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Cremer
Fibrin glue in coronary surgery
Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 559 - 559.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.